This 'positive publication bias' is a serious problem, because it can make a drug or device appear in the literature to be more effective than it is. ...
According to the Nature Medicine article, a paper in Science indicates that "the FDA Amendments Act of 2007 has improved transparency, because the law mandates that sponsors or primary investigators of clinical trials for approved drugs post a summary of their results in a national open-access database. The lead author of the report, Deborah Zarin, oversees the ClinicalTrials.gov registry at the National Library of Medicine of the US National Institutes of Health ...
Posted by
Gavin Baker at 11/28/2008 07:18:00 PM.
The open access movement:
Putting peer-reviewed scientific and scholarly literature
on the internet. Making it available free of charge and
free of most copyright and licensing restrictions.
Removing the barriers to serious research.
I recommend the OA tracking project (OATP) as the best way to stay on top of new OA developments. You can read the OATP feed on a blog-like web page or subscribe to it by RSS, email, or Twitter. You can also help build the feed by tagging new developments you encounter.
